[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fK1RcbUEOzyqH2GzQgnWIw_MEAkWrFhQK0B52TeQeez0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":43,"rows":50},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",[4],422,false,26,45,557637,2,304,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Pregnancy",29,{"name":18,"count":19},"Obesity",24,{"name":21,"count":22},"Healthy",17,{"name":24,"count":25},"Infertility",12,{"name":27,"count":28},"Osteoporosis",10,{"name":30,"count":28},"HIV Infections",{"name":32,"count":33},"Endometriosis",9,{"name":35,"count":36},"Preterm Birth",8,[38],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06851754","Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","2031-12-01","Progesterone",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,77,95,134,171,207,232,256,280,298,322,348,374,399,417,468,501,536,575,607,643,672,690,708,726,744,762,788,813,839,862,880,898,924,949,967,992,1017,1035,1062,1080,1104,1128,1155,1173,1198,1216,1240,1266,1284,1309,1334,1352,1370,1388,1406,1436,1460,1485,1529,1562,1588,1618,1645,1671,1689,1716,1743,1761,1779,1802,1824,1842,1870,1888,1906,1931,1954,1981,1999,2023,2047,2070,2096,2122,2148,2171,2195,2219,2247,2265,2283,2301,2324,2349,2375,2401,2425,2448,2470,2496,2514,2541,2559,2577,2603,2621,2639,2657,2680,2703,2721,2746,2769,2787,2813,2837,2862,2886,2909,2935,2957,2982,3005,3028,3054,3076,3114,3142,3171,3193,3222,3246,3274,3297,3322,3345,3363,3385,3403,3428,3454,3472,3490,3514,3539,3565],{"intervention":42,"totalTrials":52,"cells":53},1,{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":61,"PHASE4":73,"NA":75},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":56},[],{"trials":62,"activeCount":52,"soonestReadout":41},[63],{"nctId":39,"briefTitle":40,"status":64,"phases":65,"primaryCompletion":41,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":71},"RECRUITING",[47],"2031-12-31","2025-07-17",185,[70],"Premature Ovarian Insufficiency",[42,72],"Estrogen Patch",{"trials":74,"activeCount":56},[],{"trials":76,"activeCount":56},[],{"intervention":72,"totalTrials":52,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":91,"NA":93},{"trials":80,"activeCount":56},[],{"trials":82,"activeCount":56},[],{"trials":84,"activeCount":56},[],{"trials":86,"activeCount":52,"soonestReadout":41},[87],{"nctId":39,"briefTitle":40,"status":64,"phases":88,"primaryCompletion":41,"completion":66,"start":67,"enrollment":68,"conditions":89,"interventions":90},[47],[70],[42,72],{"trials":92,"activeCount":56},[],{"trials":94,"activeCount":56},[],{"intervention":96,"totalTrials":11,"cells":97},"testosterone enanthate",{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":118,"NA":132},{"trials":99,"activeCount":56},[],{"trials":101,"activeCount":56},[],{"trials":103,"activeCount":56},[],{"trials":105,"activeCount":56},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT00070733","The Effect of 5-Alpha Reductase on Testosterone in Men","UNKNOWN",[47],"2005-06","2003-08",184,[115],"Sex Disorders",[96,117],"duastride",{"trials":119,"activeCount":56},[120],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":113,"conditions":128,"interventions":129},"NCT00493987","The Role of 5-alpha Reductase in Mediating Testosterone Actions","COMPLETED",[48],"2009-12","2010-03","2002-11",[21],[130,131],"Testosterone Enanthate","Dutasteride",{"trials":133,"activeCount":56},[],{"intervention":135,"totalTrials":11,"cells":136},"sertraline",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":156,"NA":169},{"trials":138,"activeCount":56},[],{"trials":140,"activeCount":56},[],{"trials":142,"activeCount":56},[],{"trials":144,"activeCount":56},[145],{"nctId":146,"briefTitle":147,"status":109,"phases":148,"start":149,"conditions":150,"interventions":155},"NCT00491478","Repetitive Behavior Disorders in People With Severe Mental Retardation",[47],"1992-09",[151,152,153,154],"Mental Retardation","Stereotyped Behavior","Self-Injurious Behavior","Compulsive Behavior",[135],{"trials":157,"activeCount":56},[158],{"nctId":159,"briefTitle":160,"status":123,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT00318773","Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS)",[48],"2007-12","2008-02","2002-02",174,[167],"Premenstrual Syndrome",[135],{"trials":170,"activeCount":56},[],{"intervention":172,"totalTrials":11,"cells":173},"Amitriptyline",{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":205},{"trials":175,"activeCount":56},[],{"trials":177,"activeCount":56},[],{"trials":179,"activeCount":56},[],{"trials":181,"activeCount":56},[],{"trials":183,"activeCount":56},[184,196],{"nctId":185,"briefTitle":186,"status":123,"phases":187,"primaryCompletion":188,"start":189,"enrollment":190,"conditions":191,"interventions":195},"NCT00006427","Chronic Pain After Amputation",[48],"2001-07","1996-08",125,[192,193,194],"Amputation, Traumatic","Pain","Postoperative Pain",[172],{"nctId":197,"briefTitle":198,"status":123,"phases":199,"primaryCompletion":200,"completion":200,"start":189,"enrollment":201,"conditions":202,"interventions":204},"NCT00006428","Chronic Pain in Spinal Cord Injury",[48],"2007-05",100,[203,193],"Spinal Cord Injuries",[172],{"trials":206,"activeCount":56},[],{"intervention":208,"totalTrials":52,"cells":209},"Morphine",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":230},{"trials":211,"activeCount":56},[],{"trials":213,"activeCount":56},[],{"trials":215,"activeCount":56},[],{"trials":217,"activeCount":56},[],{"trials":219,"activeCount":56},[220],{"nctId":221,"briefTitle":222,"status":123,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT01322191","Morphine PK Subgroup Analysis",[48],"2010-11","2008-04",48,[228],"Post Operative Pain",[208],{"trials":231,"activeCount":56},[],{"intervention":233,"totalTrials":52,"cells":234},"lopinavir\u002Fritonavir (Kaletra®)",{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":254},{"trials":236,"activeCount":56},[],{"trials":238,"activeCount":56},[],{"trials":240,"activeCount":56},[],{"trials":242,"activeCount":56},[],{"trials":244,"activeCount":56},[245],{"nctId":246,"briefTitle":247,"status":123,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":25,"conditions":251,"interventions":253},"NCT00810108","Lopinavir\u002FRitonavir (Kaletra) PK in Children",[48],"2009-05","2006-06",[252,30],"HIV\u002FAIDS Treatment",[233],{"trials":255,"activeCount":56},[],{"intervention":257,"totalTrials":52,"cells":258},"Actinomycin-D",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":278},{"trials":260,"activeCount":56},[],{"trials":262,"activeCount":56},[],{"trials":264,"activeCount":56},[],{"trials":266,"activeCount":56},[],{"trials":268,"activeCount":56},[269],{"nctId":270,"briefTitle":271,"status":109,"phases":272,"start":273,"enrollment":19,"conditions":274,"interventions":276},"NCT00491946","A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer",[48],"2004-06",[275],"Cancer",[257,277],"Vincristine",{"trials":279,"activeCount":56},[],{"intervention":277,"totalTrials":52,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":296},{"trials":283,"activeCount":56},[],{"trials":285,"activeCount":56},[],{"trials":287,"activeCount":56},[],{"trials":289,"activeCount":56},[],{"trials":291,"activeCount":56},[292],{"nctId":270,"briefTitle":271,"status":109,"phases":293,"start":273,"enrollment":19,"conditions":294,"interventions":295},[48],[275],[257,277],{"trials":297,"activeCount":56},[],{"intervention":299,"totalTrials":52,"cells":300},"Cystagon",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":320},{"trials":302,"activeCount":56},[],{"trials":304,"activeCount":56},[],{"trials":306,"activeCount":56},[],{"trials":308,"activeCount":56},[],{"trials":310,"activeCount":56},[311],{"nctId":312,"briefTitle":313,"status":123,"phases":314,"primaryCompletion":315,"completion":315,"start":316,"enrollment":28,"conditions":317,"interventions":319},"NCT00028262","Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis",[48],"2013-11","2001-02",[318],"Infantile Neronal Ceroid Lipofuscinosis",[299],{"trials":321,"activeCount":56},[],{"intervention":323,"totalTrials":52,"cells":324},"doxycycline",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":346},{"trials":326,"activeCount":56},[],{"trials":328,"activeCount":56},[],{"trials":330,"activeCount":56},[],{"trials":332,"activeCount":56},[],{"trials":334,"activeCount":56},[335],{"nctId":336,"briefTitle":337,"status":109,"phases":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":345},"NCT00064766","Norplant and Irregular Bleeding\u002FSpotting",[48],"2005-02","2003-02",50,[343,344],"Endometrial Bleeding","Periodontal Disease",[323],{"trials":347,"activeCount":56},[],{"intervention":349,"totalTrials":52,"cells":350},"GnRH antagonist",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":372},{"trials":352,"activeCount":56},[],{"trials":354,"activeCount":56},[],{"trials":356,"activeCount":56},[],{"trials":358,"activeCount":56},[],{"trials":360,"activeCount":56},[361],{"nctId":362,"briefTitle":363,"status":364,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":56,"conditions":368,"interventions":371},"NCT00507780","Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy","WITHDRAWN",[48],"2010-07-22","2007-07-18",[369,370],"Ovarian Function","Preservation of Ovarian Function",[349],{"trials":373,"activeCount":56},[],{"intervention":375,"totalTrials":52,"cells":376},"emergency contraception",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":397},{"trials":378,"activeCount":56},[],{"trials":380,"activeCount":56},[],{"trials":382,"activeCount":56},[],{"trials":384,"activeCount":56},[],{"trials":386,"activeCount":56},[387],{"nctId":388,"briefTitle":389,"status":123,"phases":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":396},"NCT00067509","Emergency Contraception (ECP): Reducing Unintended Pregnancies",[48],"2004-05","2001-06",1100,[395,15],"Contraception",[375],{"trials":398,"activeCount":56},[],{"intervention":131,"totalTrials":52,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":415},{"trials":402,"activeCount":56},[],{"trials":404,"activeCount":56},[],{"trials":406,"activeCount":56},[],{"trials":408,"activeCount":56},[],{"trials":410,"activeCount":56},[411],{"nctId":121,"briefTitle":122,"status":123,"phases":412,"primaryCompletion":125,"completion":126,"start":127,"enrollment":113,"conditions":413,"interventions":414},[48],[21],[130,131],{"trials":416,"activeCount":56},[],{"intervention":418,"totalTrials":419,"cells":420},"Testolactone",3,{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":448,"PHASE4":464,"NA":466},{"trials":422,"activeCount":56},[],{"trials":424,"activeCount":56},[],{"trials":426,"activeCount":56},[427,439],{"nctId":428,"briefTitle":429,"status":123,"phases":430,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT00001202","Treatment of Boys With Precocious Puberty",[46],"2004-01","1985-01",80,[435],"Precocious Puberty",[437,418,438],"Spironolactone","Deslorelin",{"nctId":440,"briefTitle":441,"status":123,"phases":442,"completion":443,"start":444,"enrollment":201,"conditions":445,"interventions":447},"NCT00001181","Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty",[46],"2003-05","1982-10",[446,435],"Polyostotic Fibrous Dysplasia",[418],{"trials":449,"activeCount":56},[450],{"nctId":451,"briefTitle":452,"status":123,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT00001521","Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia",[47],"2024-04-01","1995-06-08",66,[458],"Congenital Adrenal Hyperplasia (CAH)",[460,461,462,463,418],"Fludrocortisone","Hydrocortisone","Letrozole","Flutamide",{"trials":465,"activeCount":56},[],{"trials":467,"activeCount":56},[],{"intervention":469,"totalTrials":11,"cells":470},"Montelukast",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":497,"NA":499},{"trials":472,"activeCount":56},[],{"trials":474,"activeCount":56},[],{"trials":476,"activeCount":56},[],{"trials":478,"activeCount":56},[479,491],{"nctId":480,"briefTitle":481,"status":109,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":490},"NCT00491790","Montelukast With Status Asthmaticus, Ages 2-5",[46,47],"2010-01","2010-10","2006-12",52,[488,489],"Status Asthmaticus","Asthma",[469],{"nctId":492,"briefTitle":493,"status":109,"phases":494,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":495,"interventions":496},"NCT00494572","Montelukast With Status Asthmaticus, Ages 6-18",[46,47],[488,489],[469],{"trials":498,"activeCount":56},[],{"trials":500,"activeCount":56},[],{"intervention":502,"totalTrials":11,"cells":503},"Lithium Carbonate",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":520,"PHASE4":532,"NA":534},{"trials":505,"activeCount":56},[],{"trials":507,"activeCount":56},[],{"trials":509,"activeCount":56},[510],{"nctId":511,"briefTitle":512,"status":123,"phases":513,"primaryCompletion":514,"completion":515,"start":485,"enrollment":516,"conditions":517,"interventions":519},"NCT00442039","Lithium for the Treatment of Pediatric Mania",[46],"2009-04","2009-09",61,[518],"Bipolar I Disorder Without Psychotic Symptoms",[502,502,502],{"trials":521,"activeCount":56},[522],{"nctId":523,"briefTitle":524,"status":123,"phases":525,"primaryCompletion":526,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":531},"NCT01166425","Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.",[46,47],"2013-04","2010-06",81,[530],"Bipolar Disorder",[502],{"trials":533,"activeCount":56},[],{"trials":535,"activeCount":56},[],{"intervention":537,"totalTrials":11,"cells":538},"Zidovudine",{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":571,"NA":573},{"trials":540,"activeCount":56},[],{"trials":542,"activeCount":56},[],{"trials":544,"activeCount":56},[],{"trials":546,"activeCount":56},[547,557],{"nctId":548,"briefTitle":549,"status":123,"phases":550,"completion":551,"enrollment":552,"conditions":553,"interventions":554},"NCT00000751","A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)",[47],"2007-08",1600,[30,15],[555,556,537],"Anti-HIV Immune Serum Globulin","Globulin, Immune",{"nctId":558,"briefTitle":559,"status":123,"phases":560,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":567},"NCT00099359","Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission",[47],"2011-02","2004-02",1735,[565,566,30],"Disease Transmission, Vertical","Vertical Human Immunodeficiency Virus Transmission",[537,568,569,570],"Nevirapine","Epivir","Nelfinavir",{"trials":572,"activeCount":56},[],{"trials":574,"activeCount":56},[],{"intervention":576,"totalTrials":11,"cells":577},"Rosiglitazone",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":594,"PHASE4":603,"NA":605},{"trials":579,"activeCount":56},[],{"trials":581,"activeCount":56},[],{"trials":583,"activeCount":56},[584],{"nctId":585,"briefTitle":586,"status":587,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":593},"NCT00115661","Use of Rosiglitazone in the Treatment of Endometriosis","TERMINATED",[46],"2006-05","2005-07",25,[32],[576],{"trials":595,"activeCount":56},[596],{"nctId":597,"briefTitle":598,"status":364,"phases":599,"primaryCompletion":600,"completion":600,"start":590,"enrollment":56,"conditions":601,"interventions":602},"NCT00121953","Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis",[46,47],"2008-05",[32],[576],{"trials":604,"activeCount":56},[],{"trials":606,"activeCount":56},[],{"intervention":608,"totalTrials":11,"cells":609},"Humatrope",{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":627,"PHASE4":639,"NA":641},{"trials":611,"activeCount":56},[],{"trials":613,"activeCount":56},[],{"trials":615,"activeCount":56},[616],{"nctId":617,"briefTitle":618,"status":123,"phases":619,"completion":620,"start":621,"enrollment":433,"conditions":622,"interventions":625},"NCT00001343","The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome",[46],"2007-10-10","1992-12-11",[623,624],"Dwarfism","Turner's Syndrome",[608,626],"Oxandrolone",{"trials":628,"activeCount":56},[629],{"nctId":630,"briefTitle":631,"status":123,"phases":632,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"NCT00001305","Growth Hormone Therapy in Osteogenesis Imperfecta",[47],"2017-05-19","1991-11-05",42,[637],"Osteogenesis Imperfecta",[608],{"trials":640,"activeCount":56},[],{"trials":642,"activeCount":56},[],{"intervention":568,"totalTrials":11,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":668,"NA":670},{"trials":646,"activeCount":56},[],{"trials":648,"activeCount":56},[],{"trials":650,"activeCount":56},[],{"trials":652,"activeCount":56},[653,657],{"nctId":558,"briefTitle":559,"status":123,"phases":654,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":655,"interventions":656},[47],[565,566,30],[537,568,569,570],{"nctId":658,"briefTitle":659,"status":109,"phases":660,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":666},"NCT00117728","Pediatric Nevirapine Resistance Study",[47],"2010-09","2005-04",250,[665,30],"AIDS",[667],"nevirapine",{"trials":669,"activeCount":56},[],{"trials":671,"activeCount":56},[],{"intervention":117,"totalTrials":52,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":686,"NA":688},{"trials":675,"activeCount":56},[],{"trials":677,"activeCount":56},[],{"trials":679,"activeCount":56},[],{"trials":681,"activeCount":56},[682],{"nctId":107,"briefTitle":108,"status":109,"phases":683,"completion":111,"start":112,"enrollment":113,"conditions":684,"interventions":685},[47],[115],[96,117],{"trials":687,"activeCount":56},[],{"trials":689,"activeCount":56},[],{"intervention":460,"totalTrials":52,"cells":691},{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":698,"PHASE4":704,"NA":706},{"trials":693,"activeCount":56},[],{"trials":695,"activeCount":56},[],{"trials":697,"activeCount":56},[],{"trials":699,"activeCount":56},[700],{"nctId":451,"briefTitle":452,"status":123,"phases":701,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":702,"interventions":703},[47],[458],[460,461,462,463,418],{"trials":705,"activeCount":56},[],{"trials":707,"activeCount":56},[],{"intervention":461,"totalTrials":52,"cells":709},{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":716,"PHASE4":722,"NA":724},{"trials":711,"activeCount":56},[],{"trials":713,"activeCount":56},[],{"trials":715,"activeCount":56},[],{"trials":717,"activeCount":56},[718],{"nctId":451,"briefTitle":452,"status":123,"phases":719,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":720,"interventions":721},[47],[458],[460,461,462,463,418],{"trials":723,"activeCount":56},[],{"trials":725,"activeCount":56},[],{"intervention":462,"totalTrials":52,"cells":727},{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":740,"NA":742},{"trials":729,"activeCount":56},[],{"trials":731,"activeCount":56},[],{"trials":733,"activeCount":56},[],{"trials":735,"activeCount":56},[736],{"nctId":451,"briefTitle":452,"status":123,"phases":737,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":738,"interventions":739},[47],[458],[460,461,462,463,418],{"trials":741,"activeCount":56},[],{"trials":743,"activeCount":56},[],{"intervention":463,"totalTrials":52,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":758,"NA":760},{"trials":747,"activeCount":56},[],{"trials":749,"activeCount":56},[],{"trials":751,"activeCount":56},[],{"trials":753,"activeCount":56},[754],{"nctId":451,"briefTitle":452,"status":123,"phases":755,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":756,"interventions":757},[47],[458],[460,461,462,463,418],{"trials":759,"activeCount":56},[],{"trials":761,"activeCount":56},[],{"intervention":763,"totalTrials":52,"cells":764},"Shigella conjugate vaccines",{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":771,"PHASE4":784,"NA":786},{"trials":766,"activeCount":56},[],{"trials":768,"activeCount":56},[],{"trials":770,"activeCount":56},[],{"trials":772,"activeCount":56},[773],{"nctId":774,"briefTitle":775,"status":123,"phases":776,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":783},"NCT00368316","Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel",[47],"2008-01","2009-02","2003-01",2799,[782],"Shigellosis",[763],{"trials":785,"activeCount":56},[],{"trials":787,"activeCount":56},[],{"intervention":789,"totalTrials":52,"cells":790},"glucose",{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":797,"PHASE4":809,"NA":811},{"trials":792,"activeCount":56},[],{"trials":794,"activeCount":56},[],{"trials":796,"activeCount":56},[],{"trials":798,"activeCount":56},[799],{"nctId":800,"briefTitle":801,"status":364,"phases":802,"completion":803,"start":804,"enrollment":56,"conditions":805,"interventions":807},"NCT00062972","Improving Memory in Patients With Multiple Sclerosis",[47],"2002-08","1999-09",[806],"Multiple Sclerosis",[808,789],"donepezil",{"trials":810,"activeCount":56},[],{"trials":812,"activeCount":56},[],{"intervention":814,"totalTrials":52,"cells":815},"Lorenzo's oil",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":822,"PHASE4":835,"NA":837},{"trials":817,"activeCount":56},[],{"trials":819,"activeCount":56},[],{"trials":821,"activeCount":56},[],{"trials":823,"activeCount":56},[824],{"nctId":825,"briefTitle":826,"status":587,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":834},"NCT00545597","A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy",[47],"2007-10","2005-03",240,[832,833],"Adrenomyeloneuropathy","Adrenoleukodystrophy",[814],{"trials":836,"activeCount":56},[],{"trials":838,"activeCount":56},[],{"intervention":840,"totalTrials":52,"cells":841},"Valproate",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":858,"NA":860},{"trials":843,"activeCount":56},[],{"trials":845,"activeCount":56},[],{"trials":847,"activeCount":56},[],{"trials":849,"activeCount":56},[850],{"nctId":851,"briefTitle":852,"status":109,"phases":853,"enrollment":854,"conditions":855,"interventions":857},"NCT00065884","Valproate Response in Aggressive Autistic Adolescents",[47],30,[856],"Autism",[840],{"trials":859,"activeCount":56},[],{"trials":861,"activeCount":56},[],{"intervention":555,"totalTrials":52,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":876,"NA":878},{"trials":865,"activeCount":56},[],{"trials":867,"activeCount":56},[],{"trials":869,"activeCount":56},[],{"trials":871,"activeCount":56},[872],{"nctId":548,"briefTitle":549,"status":123,"phases":873,"completion":551,"enrollment":552,"conditions":874,"interventions":875},[47],[30,15],[555,556,537],{"trials":877,"activeCount":56},[],{"trials":879,"activeCount":56},[],{"intervention":556,"totalTrials":52,"cells":881},{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":894,"NA":896},{"trials":883,"activeCount":56},[],{"trials":885,"activeCount":56},[],{"trials":887,"activeCount":56},[],{"trials":889,"activeCount":56},[890],{"nctId":548,"briefTitle":549,"status":123,"phases":891,"completion":551,"enrollment":552,"conditions":892,"interventions":893},[47],[30,15],[555,556,537],{"trials":895,"activeCount":56},[],{"trials":897,"activeCount":56},[],{"intervention":899,"totalTrials":52,"cells":900},"donepezil hydrochloride",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":920,"NA":922},{"trials":902,"activeCount":56},[],{"trials":904,"activeCount":56},[],{"trials":906,"activeCount":56},[],{"trials":908,"activeCount":56},[909],{"nctId":910,"briefTitle":911,"status":109,"phases":912,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":918},"NCT00069550","Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome",[47],"2008-06","2004-09",90,[917],"Rett Syndrome",[919,899],"dextromethorphan",{"trials":921,"activeCount":56},[],{"trials":923,"activeCount":56},[],{"intervention":925,"totalTrials":52,"cells":926},"Oral Contraceptive",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":945,"NA":947},{"trials":928,"activeCount":56},[],{"trials":930,"activeCount":56},[],{"trials":932,"activeCount":56},[],{"trials":934,"activeCount":56},[935],{"nctId":936,"briefTitle":937,"status":123,"phases":938,"start":939,"enrollment":940,"conditions":941,"interventions":943},"NCT00229996","Medical Treatment of Endometriosis-Associated Pelvic Pain",[47],"2004-07",194,[32,942],"Pelvic Pain",[925,944],"Depot-Leuprolide\u002FNorethindrone",{"trials":946,"activeCount":56},[],{"trials":948,"activeCount":56},[],{"intervention":944,"totalTrials":52,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":963,"NA":965},{"trials":952,"activeCount":56},[],{"trials":954,"activeCount":56},[],{"trials":956,"activeCount":56},[],{"trials":958,"activeCount":56},[959],{"nctId":936,"briefTitle":937,"status":123,"phases":960,"start":939,"enrollment":940,"conditions":961,"interventions":962},[47],[32,942],[925,944],{"trials":964,"activeCount":56},[],{"trials":966,"activeCount":56},[],{"intervention":968,"totalTrials":52,"cells":969},"citicoline",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":988,"NA":990},{"trials":971,"activeCount":56},[],{"trials":973,"activeCount":56},[],{"trials":975,"activeCount":56},[],{"trials":977,"activeCount":56},[978],{"nctId":979,"briefTitle":980,"status":587,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT00545662","Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)",[47],"2011-05","2007-07",1213,[986],"Traumatic Brain Injury",[968],{"trials":989,"activeCount":56},[],{"trials":991,"activeCount":56},[],{"intervention":993,"totalTrials":52,"cells":994},"secretin, synthetic porcine",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1013,"NA":1015},{"trials":996,"activeCount":56},[],{"trials":998,"activeCount":56},[],{"trials":1000,"activeCount":56},[],{"trials":1002,"activeCount":56},[1003],{"nctId":1004,"briefTitle":1005,"status":123,"phases":1006,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1011},"NCT00065962","Secretin for the Treatment of Autism",[47],"2000-05","1999-06",85,[856],[993,1012],"secretin, biologically derived porcine",{"trials":1014,"activeCount":56},[],{"trials":1016,"activeCount":56},[],{"intervention":1012,"totalTrials":52,"cells":1018},{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1025,"PHASE4":1031,"NA":1033},{"trials":1020,"activeCount":56},[],{"trials":1022,"activeCount":56},[],{"trials":1024,"activeCount":56},[],{"trials":1026,"activeCount":56},[1027],{"nctId":1004,"briefTitle":1005,"status":123,"phases":1028,"completion":1007,"start":1008,"enrollment":1009,"conditions":1029,"interventions":1030},[47],[856],[993,1012],{"trials":1032,"activeCount":56},[],{"trials":1034,"activeCount":56},[],{"intervention":1036,"totalTrials":52,"cells":1037},"Botulinum Toxin A, bladder detrusor muscle",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1058,"NA":1060},{"trials":1039,"activeCount":56},[],{"trials":1041,"activeCount":56},[],{"trials":1043,"activeCount":56},[],{"trials":1045,"activeCount":56},[1046],{"nctId":1047,"briefTitle":1048,"status":587,"phases":1049,"primaryCompletion":162,"completion":162,"start":250,"enrollment":1050,"conditions":1051,"interventions":1056},"NCT00373789","Refractory Urge Incontinence and Botox Injections",[47],87,[1052,1053,1054,1055],"Urinary Incontinence","Detrusor Overactivity","Urinary Urgency","Urge Urinary Incontinence",[1036,1057],"Vehicle saline as placebo",{"trials":1059,"activeCount":56},[],{"trials":1061,"activeCount":56},[],{"intervention":1057,"totalTrials":52,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1076,"NA":1078},{"trials":1065,"activeCount":56},[],{"trials":1067,"activeCount":56},[],{"trials":1069,"activeCount":56},[],{"trials":1071,"activeCount":56},[1072],{"nctId":1047,"briefTitle":1048,"status":587,"phases":1073,"primaryCompletion":162,"completion":162,"start":250,"enrollment":1050,"conditions":1074,"interventions":1075},[47],[1052,1053,1054,1055],[1036,1057],{"trials":1077,"activeCount":56},[],{"trials":1079,"activeCount":56},[],{"intervention":1081,"totalTrials":52,"cells":1082},"Calcium supplement",{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1089,"PHASE4":1100,"NA":1102},{"trials":1084,"activeCount":56},[],{"trials":1086,"activeCount":56},[],{"trials":1088,"activeCount":56},[],{"trials":1090,"activeCount":56},[1091],{"nctId":1092,"briefTitle":1093,"status":123,"phases":1094,"primaryCompletion":1095,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1099},"NCT00030238","Supplemental Calcium in Overweight People",[47],"2007-12-14","2002-02-06",540,[18],[1081],{"trials":1101,"activeCount":56},[],{"trials":1103,"activeCount":56},[],{"intervention":1105,"totalTrials":52,"cells":1106},"lorazepam or diazepam",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1124,"NA":1126},{"trials":1108,"activeCount":56},[],{"trials":1110,"activeCount":56},[],{"trials":1112,"activeCount":56},[],{"trials":1114,"activeCount":56},[1115],{"nctId":1116,"briefTitle":1117,"status":123,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":163,"enrollment":1120,"conditions":1121,"interventions":1123},"NCT00621478","Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)",[46,47],"2012-05",259,[1122],"Status Epilepticus",[1105],{"trials":1125,"activeCount":56},[],{"trials":1127,"activeCount":56},[],{"intervention":1129,"totalTrials":52,"cells":1130},"Norethindrone Acetate",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1151,"NA":1153},{"trials":1132,"activeCount":56},[],{"trials":1134,"activeCount":56},[],{"trials":1136,"activeCount":56},[],{"trials":1138,"activeCount":56},[1139],{"nctId":1140,"briefTitle":1141,"status":109,"phases":1142,"primaryCompletion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1149},"NCT00458458","Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)",[47],"2012-12","2004-08",112,[32,1147,1148],"Dysmenorrhea","Dyspareunia",[1129,1150],"GnRH Agonist",{"trials":1152,"activeCount":56},[],{"trials":1154,"activeCount":56},[],{"intervention":1150,"totalTrials":52,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1163,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":56},[],{"trials":1160,"activeCount":56},[],{"trials":1162,"activeCount":56},[],{"trials":1164,"activeCount":56},[1165],{"nctId":1140,"briefTitle":1141,"status":109,"phases":1166,"primaryCompletion":1143,"start":1144,"enrollment":1145,"conditions":1167,"interventions":1168},[47],[32,1147,1148],[1129,1150],{"trials":1170,"activeCount":56},[],{"trials":1172,"activeCount":56},[],{"intervention":1174,"totalTrials":52,"cells":1175},"metformin XR",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1194,"NA":1196},{"trials":1177,"activeCount":56},[],{"trials":1179,"activeCount":56},[],{"trials":1181,"activeCount":56},[],{"trials":1183,"activeCount":56},[1184],{"nctId":1185,"briefTitle":1186,"status":123,"phases":1187,"completion":1188,"start":127,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT00068861","Treatment of Infertility in Women With Polycystic Ovary Syndrome",[47],"2006-02",678,[1191,24,15],"Polycystic Ovary Syndrome",[1174,1193],"clomiphene citrate",{"trials":1195,"activeCount":56},[],{"trials":1197,"activeCount":56},[],{"intervention":1193,"totalTrials":52,"cells":1199},{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1206,"PHASE4":1212,"NA":1214},{"trials":1201,"activeCount":56},[],{"trials":1203,"activeCount":56},[],{"trials":1205,"activeCount":56},[],{"trials":1207,"activeCount":56},[1208],{"nctId":1185,"briefTitle":1186,"status":123,"phases":1209,"completion":1188,"start":127,"enrollment":1189,"conditions":1210,"interventions":1211},[47],[1191,24,15],[1174,1193],{"trials":1213,"activeCount":56},[],{"trials":1215,"activeCount":56},[],{"intervention":1217,"totalTrials":52,"cells":1218},"Naltrexone hydrochloride",{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1236,"NA":1238},{"trials":1220,"activeCount":56},[],{"trials":1222,"activeCount":56},[],{"trials":1224,"activeCount":56},[],{"trials":1226,"activeCount":56},[1227],{"nctId":1228,"briefTitle":1229,"status":109,"phases":1230,"completion":1231,"start":1232,"enrollment":1233,"conditions":1234,"interventions":1235},"NCT00065936","Self-Injury: Diagnosis and Treatment",[47],"2002-06","1997-07",37,[153,151],[1217],{"trials":1237,"activeCount":56},[],{"trials":1239,"activeCount":56},[],{"intervention":1241,"totalTrials":52,"cells":1242},"zinc sulphate dietary supplement",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1249,"PHASE4":1262,"NA":1264},{"trials":1244,"activeCount":56},[],{"trials":1246,"activeCount":56},[],{"trials":1248,"activeCount":56},[],{"trials":1250,"activeCount":56},[1251],{"nctId":1252,"briefTitle":1253,"status":123,"phases":1254,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1260},"NCT00109551","Community Trial of Zinc Supplementation on Preschool Child Mortality and Morbidity in Southern Nepal",[47],"2006-01","2001-10",58000,[1259],"Nutrition",[1241,1261],"iron sulphate-folic acid dietary supplement",{"trials":1263,"activeCount":56},[],{"trials":1265,"activeCount":56},[],{"intervention":1261,"totalTrials":52,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1280,"NA":1282},{"trials":1269,"activeCount":56},[],{"trials":1271,"activeCount":56},[],{"trials":1273,"activeCount":56},[],{"trials":1275,"activeCount":56},[1276],{"nctId":1252,"briefTitle":1253,"status":123,"phases":1277,"completion":1255,"start":1256,"enrollment":1257,"conditions":1278,"interventions":1279},[47],[1259],[1241,1261],{"trials":1281,"activeCount":56},[],{"trials":1283,"activeCount":56},[],{"intervention":1285,"totalTrials":52,"cells":1286},"Pamidronate",{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1293,"PHASE4":1305,"NA":1307},{"trials":1288,"activeCount":56},[],{"trials":1290,"activeCount":56},[],{"trials":1292,"activeCount":56},[],{"trials":1294,"activeCount":56},[1295],{"nctId":1296,"briefTitle":1297,"status":123,"phases":1298,"primaryCompletion":1299,"completion":1300,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1304},"NCT00005901","Pamidronate to Treat Osteogenesis Imperfecta in Children",[47],"2014-05","2015-03","2000-06",34,[637],[1285],{"trials":1306,"activeCount":56},[],{"trials":1308,"activeCount":56},[],{"intervention":1310,"totalTrials":52,"cells":1311},"risperidone",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1330,"NA":1332},{"trials":1313,"activeCount":56},[],{"trials":1315,"activeCount":56},[],{"trials":1317,"activeCount":56},[],{"trials":1319,"activeCount":56},[1320],{"nctId":1321,"briefTitle":1322,"status":123,"phases":1323,"completion":392,"start":1324,"enrollment":341,"conditions":1325,"interventions":1327},"NCT00065273","Atypical Neuroleptic Drugs in People With Mental Retardation\u002FDevelopmental Delay",[47],"1998-07",[151,1326],"Developmental Delay Disorder",[1310,1328,1329],"clozapine","olanzapine",{"trials":1331,"activeCount":56},[],{"trials":1333,"activeCount":56},[],{"intervention":1328,"totalTrials":52,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1348,"NA":1350},{"trials":1337,"activeCount":56},[],{"trials":1339,"activeCount":56},[],{"trials":1341,"activeCount":56},[],{"trials":1343,"activeCount":56},[1344],{"nctId":1321,"briefTitle":1322,"status":123,"phases":1345,"completion":392,"start":1324,"enrollment":341,"conditions":1346,"interventions":1347},[47],[151,1326],[1310,1328,1329],{"trials":1349,"activeCount":56},[],{"trials":1351,"activeCount":56},[],{"intervention":1329,"totalTrials":52,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1366,"NA":1368},{"trials":1355,"activeCount":56},[],{"trials":1357,"activeCount":56},[],{"trials":1359,"activeCount":56},[],{"trials":1361,"activeCount":56},[1362],{"nctId":1321,"briefTitle":1322,"status":123,"phases":1363,"completion":392,"start":1324,"enrollment":341,"conditions":1364,"interventions":1365},[47],[151,1326],[1310,1328,1329],{"trials":1367,"activeCount":56},[],{"trials":1369,"activeCount":56},[],{"intervention":569,"totalTrials":52,"cells":1371},{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1384,"NA":1386},{"trials":1373,"activeCount":56},[],{"trials":1375,"activeCount":56},[],{"trials":1377,"activeCount":56},[],{"trials":1379,"activeCount":56},[1380],{"nctId":558,"briefTitle":559,"status":123,"phases":1381,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":1382,"interventions":1383},[47],[565,566,30],[537,568,569,570],{"trials":1385,"activeCount":56},[],{"trials":1387,"activeCount":56},[],{"intervention":570,"totalTrials":52,"cells":1389},{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1402,"NA":1404},{"trials":1391,"activeCount":56},[],{"trials":1393,"activeCount":56},[],{"trials":1395,"activeCount":56},[],{"trials":1397,"activeCount":56},[1398],{"nctId":558,"briefTitle":559,"status":123,"phases":1399,"primaryCompletion":561,"completion":561,"start":562,"enrollment":563,"conditions":1400,"interventions":1401},[47],[565,566,30],[537,568,569,570],{"trials":1403,"activeCount":56},[],{"trials":1405,"activeCount":56},[],{"intervention":1407,"totalTrials":52,"cells":1408},"calcium",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1432,"NA":1434},{"trials":1410,"activeCount":56},[],{"trials":1412,"activeCount":56},[],{"trials":1414,"activeCount":56},[],{"trials":1416,"activeCount":56},[1417],{"nctId":1418,"briefTitle":1419,"status":123,"phases":1420,"completion":1301,"start":1421,"conditions":1422,"interventions":1431},"NCT00000534","Calcium for Pre-Eclampsia Prevention (CPEP)",[47],"1991-03",[1423,1424,1425,1426,1427,1428,1429,1430],"Cardiovascular Diseases","Eclampsia","Heart Diseases","HELLP Syndrome","Hypertension","Pre-Eclampsia","Pregnancy Toxemias","Vascular Diseases",[1407],{"trials":1433,"activeCount":56},[],{"trials":1435,"activeCount":56},[],{"intervention":1437,"totalTrials":52,"cells":1438},"magnesium sulfate",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1456,"NA":1458},{"trials":1440,"activeCount":56},[],{"trials":1442,"activeCount":56},[],{"trials":1444,"activeCount":56},[],{"trials":1446,"activeCount":56},[1447],{"nctId":1448,"briefTitle":1449,"status":109,"phases":1450,"completion":340,"start":1451,"conditions":1452,"interventions":1455},"NCT00065949","Magnesium Sulfate to Prevent Brain Injury in Premature Infants",[47],"1987-08",[1453,1454],"Brain Injuries","Cerebral Palsy",[1437],{"trials":1457,"activeCount":56},[],{"trials":1459,"activeCount":56},[],{"intervention":1461,"totalTrials":52,"cells":1462},"Pegvisomant",{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1481,"NA":1483},{"trials":1464,"activeCount":56},[],{"trials":1466,"activeCount":56},[],{"trials":1468,"activeCount":56},[],{"trials":1470,"activeCount":56},[1471],{"nctId":1472,"briefTitle":1473,"status":123,"phases":1474,"primaryCompletion":1475,"completion":1476,"start":1477,"enrollment":25,"conditions":1478,"interventions":1480},"NCT03882034","Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess",[47],"2025-09-08","2025-09-30","2019-10-21",[1479],"Pituitary Disease",[1461],{"trials":1482,"activeCount":56},[],{"trials":1484,"activeCount":56},[],{"intervention":1486,"totalTrials":419,"cells":1487},"CDB-2914",{"EARLY_PHASE1":1488,"PHASE1":1499,"PHASE2":1510,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1489,"activeCount":56},[1490],{"nctId":1491,"briefTitle":1492,"status":364,"phases":1493,"primaryCompletion":1494,"completion":1494,"start":1495,"enrollment":56,"conditions":1496,"interventions":1498},"NCT01493791","CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women",[44],"2013-07-24","2011-11-08",[1497],"Urogenital Abnormalities",[1486],{"trials":1500,"activeCount":56},[1501],{"nctId":1502,"briefTitle":1503,"status":123,"phases":1504,"completion":829,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1508},"NCT00041899","Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914",[45],"2002-05",15,[21],[1486,1509],"COB-2914",{"trials":1511,"activeCount":56},[1512],{"nctId":1513,"briefTitle":1514,"status":123,"phases":1515,"primaryCompletion":1516,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT00044876","Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist",[46],"2007-06-16","2015-10-01","2002-09-02",56,[1521],"Leiomyoma",[1486],{"trials":1524,"activeCount":56},[],{"trials":1526,"activeCount":56},[],{"trials":1528,"activeCount":56},[],{"intervention":1530,"totalTrials":11,"cells":1531},"TMTDS",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1533,"activeCount":56},[],{"trials":1535,"activeCount":56},[],{"trials":1537,"activeCount":56},[1538,1547],{"nctId":1539,"briefTitle":1540,"status":123,"phases":1541,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT00013546","Hormone Replacement Therapy to Treat Turner Syndrome",[46],"2002-12","2001-03",92,[27,624],[1530],{"nctId":1548,"briefTitle":1549,"status":123,"phases":1550,"completion":1551,"start":1552,"enrollment":663,"conditions":1553,"interventions":1555},"NCT00001951","Hormone Replacement in Young Women With Premature Ovarian Failure",[46],"2006-10","1999-12",[21,27,1554],"Premature Ovarian Failure",[1530],{"trials":1557,"activeCount":56},[],{"trials":1559,"activeCount":56},[],{"trials":1561,"activeCount":56},[],{"intervention":438,"totalTrials":11,"cells":1563},{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1565,"activeCount":56},[],{"trials":1567,"activeCount":56},[],{"trials":1569,"activeCount":56},[1570,1574],{"nctId":428,"briefTitle":429,"status":123,"phases":1571,"completion":431,"start":432,"enrollment":433,"conditions":1572,"interventions":1573},[46],[435],[437,418,438],{"nctId":1575,"briefTitle":1576,"status":123,"phases":1577,"completion":1256,"start":1578,"enrollment":341,"conditions":1579,"interventions":1581},"NCT00001190","Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature",[46],"1983-11",[623,1580],"Growth Disorder",[438],{"trials":1583,"activeCount":56},[],{"trials":1585,"activeCount":56},[],{"trials":1587,"activeCount":56},[],{"intervention":1589,"totalTrials":11,"cells":1590},"tin mesoporphyrin",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1612,"PHASE4":1614,"NA":1616},{"trials":1592,"activeCount":56},[],{"trials":1594,"activeCount":56},[],{"trials":1596,"activeCount":56},[1597,1606],{"nctId":1598,"briefTitle":1599,"status":123,"phases":1600,"start":1552,"conditions":1601,"interventions":1605},"NCT00004381","Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia",[46],[1602,1603,1604],"Glucosephosphate Dehydrogenase Deficiency","Hyperbilirubinemia","Hemolytic Disease of Newborn",[1589],{"nctId":1607,"briefTitle":1608,"status":123,"phases":1609,"primaryCompletion":551,"start":1552,"enrollment":433,"conditions":1610,"interventions":1611},"NCT00004382","Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns",[46],[1603],[1589],{"trials":1613,"activeCount":56},[],{"trials":1615,"activeCount":56},[],{"trials":1617,"activeCount":56},[],{"intervention":1619,"totalTrials":52,"cells":1620},"Growth Hormone Therapy",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1625,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1622,"activeCount":56},[],{"trials":1624,"activeCount":56},[],{"trials":1626,"activeCount":56},[1627],{"nctId":1628,"briefTitle":1629,"status":123,"phases":1630,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1638},"NCT00102258","Role of Nutrition and Hormones in Boys With Disordered Growth",[46],"2007-10-02","2005-01-19",20,[1635,1636,1637],"Short Stature","Constitutional Delay of Growth and Development","Dwarfism, Pituitary",[1619],{"trials":1640,"activeCount":56},[],{"trials":1642,"activeCount":56},[],{"trials":1644,"activeCount":56},[],{"intervention":1646,"totalTrials":52,"cells":1647},"Colchicine 0.6Mg Cap",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1649,"activeCount":56},[],{"trials":1651,"activeCount":56},[],{"trials":1653,"activeCount":56},[1654],{"nctId":1655,"briefTitle":1656,"status":123,"phases":1657,"primaryCompletion":1658,"completion":1658,"start":1659,"enrollment":1660,"conditions":1661,"interventions":1663},"NCT02153983","Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome",[45,46],"2018-08-15","2014-05-31",77,[18,1662],"Metabolic Disease",[1646,1664],"Colchicine 0.6Mg Tab",{"trials":1666,"activeCount":56},[],{"trials":1668,"activeCount":56},[],{"trials":1670,"activeCount":56},[],{"intervention":1664,"totalTrials":52,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":56},[],{"trials":1676,"activeCount":56},[],{"trials":1678,"activeCount":56},[1679],{"nctId":1655,"briefTitle":1656,"status":123,"phases":1680,"primaryCompletion":1658,"completion":1658,"start":1659,"enrollment":1660,"conditions":1681,"interventions":1682},[45,46],[18,1662],[1646,1664],{"trials":1684,"activeCount":56},[],{"trials":1686,"activeCount":56},[],{"trials":1688,"activeCount":56},[],{"intervention":1690,"totalTrials":52,"cells":1691},"follicle stimulating hormone",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1693,"activeCount":56},[],{"trials":1695,"activeCount":56},[],{"trials":1697,"activeCount":56},[1698],{"nctId":1699,"briefTitle":1700,"status":587,"phases":1701,"primaryCompletion":1702,"completion":1702,"start":1703,"enrollment":1704,"conditions":1705,"interventions":1708},"NCT00064987","Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism",[46],"2012-10","2001-04",19,[1706,1707],"Hypogonadism","Kallmann Syndrome",[1709,1690],"gonadotropin releasing hormone",{"trials":1711,"activeCount":56},[],{"trials":1713,"activeCount":56},[],{"trials":1715,"activeCount":56},[],{"intervention":1717,"totalTrials":52,"cells":1718},"Vi-rEPA conjugate vaccine for typhoid fever",{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1720,"activeCount":56},[],{"trials":1722,"activeCount":56},[],{"trials":1724,"activeCount":56},[1725],{"nctId":1726,"briefTitle":1727,"status":123,"phases":1728,"primaryCompletion":225,"completion":1729,"start":1730,"enrollment":1731,"conditions":1732,"interventions":1734},"NCT00342628","Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants",[46],"2011-01","2006-07",301,[1733],"Typhoid Fever",[1717,1735,1736],"Hib-TT","DTP",{"trials":1738,"activeCount":56},[],{"trials":1740,"activeCount":56},[],{"trials":1742,"activeCount":56},[],{"intervention":1735,"totalTrials":52,"cells":1744},{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1746,"activeCount":56},[],{"trials":1748,"activeCount":56},[],{"trials":1750,"activeCount":56},[1751],{"nctId":1726,"briefTitle":1727,"status":123,"phases":1752,"primaryCompletion":225,"completion":1729,"start":1730,"enrollment":1731,"conditions":1753,"interventions":1754},[46],[1733],[1717,1735,1736],{"trials":1756,"activeCount":56},[],{"trials":1758,"activeCount":56},[],{"trials":1760,"activeCount":56},[],{"intervention":1736,"totalTrials":52,"cells":1762},{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1764,"activeCount":56},[],{"trials":1766,"activeCount":56},[],{"trials":1768,"activeCount":56},[1769],{"nctId":1726,"briefTitle":1727,"status":123,"phases":1770,"primaryCompletion":225,"completion":1729,"start":1730,"enrollment":1731,"conditions":1771,"interventions":1772},[46],[1733],[1717,1735,1736],{"trials":1774,"activeCount":56},[],{"trials":1776,"activeCount":56},[],{"trials":1778,"activeCount":56},[],{"intervention":1780,"totalTrials":52,"cells":1781},"Botulinum toxin type A",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1796,"PHASE4":1798,"NA":1800},{"trials":1783,"activeCount":56},[],{"trials":1785,"activeCount":56},[],{"trials":1787,"activeCount":56},[1788],{"nctId":1789,"briefTitle":1790,"status":123,"phases":1791,"primaryCompletion":1231,"start":1232,"enrollment":1792,"conditions":1793,"interventions":1795},"NCT00060957","Botulinum Toxin (BOTOX) for Cerebral Palsy",[46],40,[1454,1794],"Muscle Spasticity",[1780],{"trials":1797,"activeCount":56},[],{"trials":1799,"activeCount":56},[],{"trials":1801,"activeCount":56},[],{"intervention":1803,"totalTrials":52,"cells":1804},"Clonidine",{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1806,"activeCount":56},[],{"trials":1808,"activeCount":56},[],{"trials":1810,"activeCount":56},[1811],{"nctId":1812,"briefTitle":1813,"status":364,"phases":1814,"enrollment":56,"conditions":1815,"interventions":1817},"NCT00166686","Clonidine for Neurocognitive Sequelae",[45,46],[1816],"Treatment-Related Cancer",[1803],{"trials":1819,"activeCount":56},[],{"trials":1821,"activeCount":56},[],{"trials":1823,"activeCount":56},[],{"intervention":437,"totalTrials":52,"cells":1825},{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1830,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1827,"activeCount":56},[],{"trials":1829,"activeCount":56},[],{"trials":1831,"activeCount":56},[1832],{"nctId":428,"briefTitle":429,"status":123,"phases":1833,"completion":431,"start":432,"enrollment":433,"conditions":1834,"interventions":1835},[46],[435],[437,418,438],{"trials":1837,"activeCount":56},[],{"trials":1839,"activeCount":56},[],{"trials":1841,"activeCount":56},[],{"intervention":1843,"totalTrials":52,"cells":1844},"Pentetreotide",{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1846,"activeCount":56},[],{"trials":1848,"activeCount":56},[],{"trials":1850,"activeCount":56},[1851],{"nctId":1852,"briefTitle":1853,"status":123,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1861},"NCT00001849","New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome",[46],"2019-04-26","1999-05-20",95,[1859,1860],"Cushing Syndrome","Endocrine Disease",[1843,1862,1863],"18F-DOPA","18-FDG",{"trials":1865,"activeCount":56},[],{"trials":1867,"activeCount":56},[],{"trials":1869,"activeCount":56},[],{"intervention":1862,"totalTrials":52,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1882,"PHASE4":1884,"NA":1886},{"trials":1873,"activeCount":56},[],{"trials":1875,"activeCount":56},[],{"trials":1877,"activeCount":56},[1878],{"nctId":1852,"briefTitle":1853,"status":123,"phases":1879,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":1880,"interventions":1881},[46],[1859,1860],[1843,1862,1863],{"trials":1883,"activeCount":56},[],{"trials":1885,"activeCount":56},[],{"trials":1887,"activeCount":56},[],{"intervention":1863,"totalTrials":52,"cells":1889},{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1900,"PHASE4":1902,"NA":1904},{"trials":1891,"activeCount":56},[],{"trials":1893,"activeCount":56},[],{"trials":1895,"activeCount":56},[1896],{"nctId":1852,"briefTitle":1853,"status":123,"phases":1897,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":1898,"interventions":1899},[46],[1859,1860],[1843,1862,1863],{"trials":1901,"activeCount":56},[],{"trials":1903,"activeCount":56},[],{"trials":1905,"activeCount":56},[],{"intervention":1907,"totalTrials":52,"cells":1908},"CDB 2914",{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1910,"activeCount":56},[],{"trials":1912,"activeCount":56},[],{"trials":1914,"activeCount":56},[1915],{"nctId":1916,"briefTitle":1917,"status":123,"phases":1918,"completion":1919,"start":1920,"enrollment":1921,"conditions":1922,"interventions":1924},"NCT00009659","Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause",[46],"2001-12","2001-01",58,[1923],"Postmenopause",[1907],{"trials":1926,"activeCount":56},[],{"trials":1928,"activeCount":56},[],{"trials":1930,"activeCount":56},[],{"intervention":1932,"totalTrials":52,"cells":1933},"Alendronate",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1935,"activeCount":56},[],{"trials":1937,"activeCount":56},[],{"trials":1939,"activeCount":56},[1940],{"nctId":1941,"briefTitle":1942,"status":123,"phases":1943,"completion":1944,"start":1945,"enrollment":341,"conditions":1946,"interventions":1947},"NCT00001720","Treatment of Childhood Osteoporosis With Alendronate (Fosamax)",[46],"2003-06","1998-03",[27],[1932],{"trials":1949,"activeCount":56},[],{"trials":1951,"activeCount":56},[],{"trials":1953,"activeCount":56},[],{"intervention":1955,"totalTrials":52,"cells":1956},"Synthetic Human Parathyroid Hormone 1-34",{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1958,"activeCount":56},[],{"trials":1960,"activeCount":56},[],{"trials":1962,"activeCount":56},[1963],{"nctId":1964,"briefTitle":1965,"status":123,"phases":1966,"primaryCompletion":1967,"completion":1968,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1973},"NCT00001304","Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34",[46],"2014-03","2014-04","1991-10",27,[1972],"Hypoparathyroidism",[1955,1974],"Calcitriol & Calcium",{"trials":1976,"activeCount":56},[],{"trials":1978,"activeCount":56},[],{"trials":1980,"activeCount":56},[],{"intervention":1974,"totalTrials":52,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1984,"activeCount":56},[],{"trials":1986,"activeCount":56},[],{"trials":1988,"activeCount":56},[1989],{"nctId":1964,"briefTitle":1965,"status":123,"phases":1990,"primaryCompletion":1967,"completion":1968,"start":1969,"enrollment":1970,"conditions":1991,"interventions":1992},[46],[1972],[1955,1974],{"trials":1994,"activeCount":56},[],{"trials":1996,"activeCount":56},[],{"trials":1998,"activeCount":56},[],{"intervention":2000,"totalTrials":52,"cells":2001},"Vorinostat",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":2003,"activeCount":56},[],{"trials":2005,"activeCount":56},[],{"trials":2007,"activeCount":56},[2008],{"nctId":2009,"briefTitle":2010,"status":123,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":2013,"enrollment":25,"conditions":2014,"interventions":2016},"NCT02124083","Phase 1\u002F2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1",[45,46],"2016-12-13","2014-04-25",[2015],"Neimann-Pick Disease",[2000],{"trials":2018,"activeCount":56},[],{"trials":2020,"activeCount":56},[],{"trials":2022,"activeCount":56},[],{"intervention":2024,"totalTrials":52,"cells":2025},"N-Acetyl Cysteine",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2027,"activeCount":56},[],{"trials":2029,"activeCount":56},[],{"trials":2031,"activeCount":56},[2032],{"nctId":2033,"briefTitle":2034,"status":123,"phases":2035,"primaryCompletion":224,"completion":224,"start":2036,"enrollment":2037,"conditions":2038,"interventions":2040},"NCT00975689","Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine",[45,46],"2009-08",35,[2039],"Niemann-Pick Disease, Type C",[2024],{"trials":2042,"activeCount":56},[],{"trials":2044,"activeCount":56},[],{"trials":2046,"activeCount":56},[],{"intervention":2048,"totalTrials":52,"cells":2049},"baclofen",{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2064,"PHASE4":2066,"NA":2068},{"trials":2051,"activeCount":56},[],{"trials":2053,"activeCount":56},[],{"trials":2055,"activeCount":56},[2056],{"nctId":2057,"briefTitle":2058,"status":123,"phases":2059,"primaryCompletion":1729,"completion":1729,"start":2060,"enrollment":516,"conditions":2061,"interventions":2063},"NCT00607542","Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity",[45,46],"2008-11",[2062,1454],"Spasticity",[2048],{"trials":2065,"activeCount":56},[],{"trials":2067,"activeCount":56},[],{"trials":2069,"activeCount":56},[],{"intervention":2071,"totalTrials":52,"cells":2072},"Lo-Ovral Oral Contraceptive Pills",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":2074,"activeCount":56},[],{"trials":2076,"activeCount":56},[],{"trials":2078,"activeCount":56},[2079],{"nctId":2080,"briefTitle":2081,"status":587,"phases":2082,"primaryCompletion":2083,"completion":2083,"start":2084,"enrollment":52,"conditions":2085,"interventions":2089},"NCT00556400","Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones",[45,46],"2012-06","2007-11",[2086,2087,2088],"Aplastic Anemia","Menorrhagia","Amenorrhea",[2071],{"trials":2091,"activeCount":56},[],{"trials":2093,"activeCount":56},[],{"trials":2095,"activeCount":56},[],{"intervention":2097,"totalTrials":52,"cells":2098},"Pirfenidone",{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2100,"activeCount":56},[],{"trials":2102,"activeCount":56},[],{"trials":2104,"activeCount":56},[2105],{"nctId":2106,"briefTitle":2107,"status":123,"phases":2108,"completion":2109,"start":2110,"enrollment":2111,"conditions":2112,"interventions":2115},"NCT00332033","Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)",[46],"2007-02-16","2006-05-25",32,[2113,2114],"Uterine Leiomyoma","Fibroids",[2097],{"trials":2117,"activeCount":56},[],{"trials":2119,"activeCount":56},[],{"trials":2121,"activeCount":56},[],{"intervention":2123,"totalTrials":52,"cells":2124},"Copper Histidine",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2126,"activeCount":56},[],{"trials":2128,"activeCount":56},[],{"trials":2130,"activeCount":56},[2131],{"nctId":2132,"briefTitle":2133,"status":123,"phases":2134,"primaryCompletion":2135,"completion":2136,"start":2137,"enrollment":2138,"conditions":2139,"interventions":2141},"NCT00001262","Copper Histidine Therapy for Menkes Diseases",[45,46],"2012-07","2013-07","1990-06",60,[2140],"Kinky Hair Syndrome",[2123],{"trials":2143,"activeCount":56},[],{"trials":2145,"activeCount":56},[],{"trials":2147,"activeCount":56},[],{"intervention":2149,"totalTrials":52,"cells":2150},"lymphocyte gene therapy",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2152,"activeCount":56},[],{"trials":2154,"activeCount":56},[],{"trials":2156,"activeCount":56},[2157],{"nctId":2158,"briefTitle":2159,"status":123,"phases":2160,"start":2161,"enrollment":11,"conditions":2162,"interventions":2164},"NCT00004454","Phase I\u002FII Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)",[45,46],"1996-10",[2163],"Mucopolysaccharidosis II",[2149],{"trials":2166,"activeCount":56},[],{"trials":2168,"activeCount":56},[],{"trials":2170,"activeCount":56},[],{"intervention":2172,"totalTrials":52,"cells":2173},"Mifepristone",{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2189,"PHASE4":2191,"NA":2193},{"trials":2175,"activeCount":56},[],{"trials":2177,"activeCount":56},[],{"trials":2179,"activeCount":56},[2180],{"nctId":2181,"briefTitle":2182,"status":123,"phases":2183,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":1704,"conditions":2186,"interventions":2188},"NCT01419535","Mifepristone Effects on Glucose Intolerance in Obese\u002FOverweight Adults",[45,46],"2015-11-24","2011-11-29",[1860,2187],"Diabetes",[2172],{"trials":2190,"activeCount":56},[],{"trials":2192,"activeCount":56},[],{"trials":2194,"activeCount":56},[],{"intervention":2196,"totalTrials":52,"cells":2197},"morphine and mexiletine",{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2199,"activeCount":56},[],{"trials":2201,"activeCount":56},[],{"trials":2203,"activeCount":56},[2204],{"nctId":2205,"briefTitle":2206,"status":123,"phases":2207,"completion":2208,"start":1232,"enrollment":2138,"conditions":2209,"interventions":2212},"NCT00383682","Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain",[46],"2003-04",[2210,2211],"Amputation","Chronic Pain",[2196],{"trials":2214,"activeCount":56},[],{"trials":2216,"activeCount":56},[],{"trials":2218,"activeCount":56},[],{"intervention":2220,"totalTrials":52,"cells":2221},"Niacin First",{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2223,"activeCount":56},[],{"trials":2225,"activeCount":56},[],{"trials":2227,"activeCount":56},[2228],{"nctId":2229,"briefTitle":2230,"status":587,"phases":2231,"primaryCompletion":2232,"completion":2233,"start":2234,"enrollment":1233,"conditions":2235,"interventions":2237},"NCT01237041","Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children",[45,46],"2017-10-17","2017-12-13","2011-07-01",[18,1635,2236],"Growth Hormone Deficiency",[2220,2238,2239,2240],"Dose-Establishing Study 1 Niacin 250mg","Dose-Establishing Study 1 Niacin 500mg","Dose-Establishing Study 2 Niacin 500mg",{"trials":2242,"activeCount":56},[],{"trials":2244,"activeCount":56},[],{"trials":2246,"activeCount":56},[],{"intervention":2238,"totalTrials":52,"cells":2248},{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2259,"PHASE4":2261,"NA":2263},{"trials":2250,"activeCount":56},[],{"trials":2252,"activeCount":56},[],{"trials":2254,"activeCount":56},[2255],{"nctId":2229,"briefTitle":2230,"status":587,"phases":2256,"primaryCompletion":2232,"completion":2233,"start":2234,"enrollment":1233,"conditions":2257,"interventions":2258},[45,46],[18,1635,2236],[2220,2238,2239,2240],{"trials":2260,"activeCount":56},[],{"trials":2262,"activeCount":56},[],{"trials":2264,"activeCount":56},[],{"intervention":2239,"totalTrials":52,"cells":2266},{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2277,"PHASE4":2279,"NA":2281},{"trials":2268,"activeCount":56},[],{"trials":2270,"activeCount":56},[],{"trials":2272,"activeCount":56},[2273],{"nctId":2229,"briefTitle":2230,"status":587,"phases":2274,"primaryCompletion":2232,"completion":2233,"start":2234,"enrollment":1233,"conditions":2275,"interventions":2276},[45,46],[18,1635,2236],[2220,2238,2239,2240],{"trials":2278,"activeCount":56},[],{"trials":2280,"activeCount":56},[],{"trials":2282,"activeCount":56},[],{"intervention":2240,"totalTrials":52,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2295,"PHASE4":2297,"NA":2299},{"trials":2286,"activeCount":56},[],{"trials":2288,"activeCount":56},[],{"trials":2290,"activeCount":56},[2291],{"nctId":2229,"briefTitle":2230,"status":587,"phases":2292,"primaryCompletion":2232,"completion":2233,"start":2234,"enrollment":1233,"conditions":2293,"interventions":2294},[45,46],[18,1635,2236],[2220,2238,2239,2240],{"trials":2296,"activeCount":56},[],{"trials":2298,"activeCount":56},[],{"trials":2300,"activeCount":56},[],{"intervention":2302,"totalTrials":52,"cells":2303},"Raloxifene",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2305,"activeCount":56},[],{"trials":2307,"activeCount":56},[],{"trials":2309,"activeCount":56},[2310],{"nctId":2311,"briefTitle":2312,"status":123,"phases":2313,"completion":1255,"start":2314,"enrollment":2315,"conditions":2316,"interventions":2317},"NCT00001848","The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis",[46],"1998-11",612,[32,942],[2302],{"trials":2319,"activeCount":56},[],{"trials":2321,"activeCount":56},[],{"trials":2323,"activeCount":56},[],{"intervention":2325,"totalTrials":52,"cells":2326},"Growth Hormone",{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2328,"activeCount":56},[],{"trials":2330,"activeCount":56},[],{"trials":2332,"activeCount":56},[2333],{"nctId":2334,"briefTitle":2335,"status":123,"phases":2336,"completion":2337,"start":2338,"enrollment":2339,"conditions":2340,"interventions":2342},"NCT00001221","Effect of Biosynthetic Growth Hormone and\u002For Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome",[46],"2003-09","1987-09",160,[2341,624],"Gonadal Dysgenesis",[2325],{"trials":2344,"activeCount":56},[],{"trials":2346,"activeCount":56},[],{"trials":2348,"activeCount":56},[],{"intervention":2350,"totalTrials":52,"cells":2351},"Zolpidem",{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2353,"activeCount":56},[],{"trials":2355,"activeCount":56},[],{"trials":2357,"activeCount":56},[2358],{"nctId":2359,"briefTitle":2360,"status":123,"phases":2361,"completion":2362,"start":2363,"enrollment":2364,"conditions":2365,"interventions":2368},"NCT00494468","Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children",[45,46],"2004-03","2002-10",63,[2366,2367],"Insomnia","Sleep Disorder",[2350],{"trials":2370,"activeCount":56},[],{"trials":2372,"activeCount":56},[],{"trials":2374,"activeCount":56},[],{"intervention":2376,"totalTrials":52,"cells":2377},"Colchicine",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2379,"activeCount":56},[],{"trials":2381,"activeCount":56},[],{"trials":2383,"activeCount":56},[2384],{"nctId":2385,"briefTitle":2386,"status":123,"phases":2387,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":2390,"conditions":2391,"interventions":2394},"NCT05017571","Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity",[46],"2025-09-02","2021-11-08",152,[18,2392,2393],"Insulin Resistance","Inflammation",[2376],{"trials":2396,"activeCount":56},[],{"trials":2398,"activeCount":56},[],{"trials":2400,"activeCount":56},[],{"intervention":2402,"totalTrials":52,"cells":2403},"VTS-270",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2419,"PHASE4":2421,"NA":2423},{"trials":2405,"activeCount":56},[],{"trials":2407,"activeCount":56},[],{"trials":2409,"activeCount":56},[2410],{"nctId":2411,"briefTitle":2412,"status":587,"phases":2413,"primaryCompletion":2414,"completion":2414,"start":2415,"enrollment":11,"conditions":2416,"interventions":2418},"NCT03887533","Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1",[45,46],"2021-10-25","2020-01-06",[2417],"Niemann-Pick Disease, Type C1",[2402],{"trials":2420,"activeCount":56},[],{"trials":2422,"activeCount":56},[],{"trials":2424,"activeCount":56},[],{"intervention":2426,"totalTrials":52,"cells":2427},"Dichloroacetate",{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2442,"PHASE4":2444,"NA":2446},{"trials":2429,"activeCount":56},[],{"trials":2431,"activeCount":56},[],{"trials":2433,"activeCount":56},[2434],{"nctId":2435,"briefTitle":2436,"status":109,"phases":2437,"start":2438,"enrollment":2037,"conditions":2439,"interventions":2441},"NCT00068913","Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome",[46],"2000-03",[2440],"MELAS Syndrome",[2426],{"trials":2443,"activeCount":56},[],{"trials":2445,"activeCount":56},[],{"trials":2447,"activeCount":56},[],{"intervention":2449,"totalTrials":52,"cells":2450},"nitroprusside",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2452,"activeCount":56},[],{"trials":2454,"activeCount":56},[],{"trials":2456,"activeCount":56},[2457],{"nctId":2458,"briefTitle":2459,"status":123,"phases":2460,"primaryCompletion":1729,"completion":1729,"start":2461,"enrollment":9,"conditions":2462,"interventions":2463},"NCT00621816","Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)",[46],"2009-01",[1427],[2449],{"trials":2465,"activeCount":56},[],{"trials":2467,"activeCount":56},[],{"trials":2469,"activeCount":56},[],{"intervention":2471,"totalTrials":52,"cells":2472},"Anastrozole",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2474,"activeCount":56},[],{"trials":2476,"activeCount":56},[],{"trials":2478,"activeCount":56},[2479],{"nctId":2480,"briefTitle":2481,"status":364,"phases":2482,"completion":2483,"start":589,"enrollment":2484,"conditions":2485,"interventions":2487},"NCT00382057","Testosterone Effects on Men With the Metabolic Syndrome",[46],"2011-03",72,[2486],"Metabolic Syndrome",[2488,2471,2489],"Testosterone","Goserelin",{"trials":2491,"activeCount":56},[],{"trials":2493,"activeCount":56},[],{"trials":2495,"activeCount":56},[],{"intervention":2489,"totalTrials":52,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2499,"activeCount":56},[],{"trials":2501,"activeCount":56},[],{"trials":2503,"activeCount":56},[2504],{"nctId":2480,"briefTitle":2481,"status":364,"phases":2505,"completion":2483,"start":589,"enrollment":2484,"conditions":2506,"interventions":2507},[46],[2486],[2488,2471,2489],{"trials":2509,"activeCount":56},[],{"trials":2511,"activeCount":56},[],{"trials":2513,"activeCount":56},[],{"intervention":2515,"totalTrials":52,"cells":2516},"Glyburide",{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2518,"activeCount":56},[],{"trials":2520,"activeCount":56},[],{"trials":2522,"activeCount":56},[2523],{"nctId":2524,"briefTitle":2525,"status":123,"phases":2526,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":2530,"interventions":2532},"NCT01329016","Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)",[45,46],"2015-02-28","2011-07",177,[2531],"Gestational Diabetes Mellitus",[2515,2533,2534],"Metformin","Glyburide-Metformin combination",{"trials":2536,"activeCount":56},[],{"trials":2538,"activeCount":56},[],{"trials":2540,"activeCount":56},[],{"intervention":2533,"totalTrials":52,"cells":2542},{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2544,"activeCount":56},[],{"trials":2546,"activeCount":56},[],{"trials":2548,"activeCount":56},[2549],{"nctId":2524,"briefTitle":2525,"status":123,"phases":2550,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":2551,"interventions":2552},[45,46],[2531],[2515,2533,2534],{"trials":2554,"activeCount":56},[],{"trials":2556,"activeCount":56},[],{"trials":2558,"activeCount":56},[],{"intervention":2534,"totalTrials":52,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2562,"activeCount":56},[],{"trials":2564,"activeCount":56},[],{"trials":2566,"activeCount":56},[2567],{"nctId":2524,"briefTitle":2525,"status":123,"phases":2568,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":2569,"interventions":2570},[45,46],[2531],[2515,2533,2534],{"trials":2572,"activeCount":56},[],{"trials":2574,"activeCount":56},[],{"trials":2576,"activeCount":56},[],{"intervention":2578,"totalTrials":52,"cells":2579},"[131]I-MIBG",{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2581,"activeCount":56},[],{"trials":2583,"activeCount":56},[],{"trials":2585,"activeCount":56},[2586],{"nctId":2587,"briefTitle":2588,"status":123,"phases":2589,"completion":2590,"start":2591,"enrollment":2111,"conditions":2592,"interventions":2594},"NCT00028106","131MIBG to Treat Malignant Pheochromocytoma",[46],"2007-01-08","2001-12-05",[2593],"Pheochromocytoma",[2578,2595,2596],"6-[18F]Fluorodopamine","[123]I-MIBG",{"trials":2598,"activeCount":56},[],{"trials":2600,"activeCount":56},[],{"trials":2602,"activeCount":56},[],{"intervention":2595,"totalTrials":52,"cells":2604},{"EARLY_PHASE1":2605,"PHASE1":2607,"PHASE2":2609,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2606,"activeCount":56},[],{"trials":2608,"activeCount":56},[],{"trials":2610,"activeCount":56},[2611],{"nctId":2587,"briefTitle":2588,"status":123,"phases":2612,"completion":2590,"start":2591,"enrollment":2111,"conditions":2613,"interventions":2614},[46],[2593],[2578,2595,2596],{"trials":2616,"activeCount":56},[],{"trials":2618,"activeCount":56},[],{"trials":2620,"activeCount":56},[],{"intervention":2596,"totalTrials":52,"cells":2622},{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2624,"activeCount":56},[],{"trials":2626,"activeCount":56},[],{"trials":2628,"activeCount":56},[2629],{"nctId":2587,"briefTitle":2588,"status":123,"phases":2630,"completion":2590,"start":2591,"enrollment":2111,"conditions":2631,"interventions":2632},[46],[2593],[2578,2595,2596],{"trials":2634,"activeCount":56},[],{"trials":2636,"activeCount":56},[],{"trials":2638,"activeCount":56},[],{"intervention":626,"totalTrials":52,"cells":2640},{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2645,"PHASE3":2651,"PHASE4":2653,"NA":2655},{"trials":2642,"activeCount":56},[],{"trials":2644,"activeCount":56},[],{"trials":2646,"activeCount":56},[2647],{"nctId":617,"briefTitle":618,"status":123,"phases":2648,"completion":620,"start":621,"enrollment":433,"conditions":2649,"interventions":2650},[46],[623,624],[608,626],{"trials":2652,"activeCount":56},[],{"trials":2654,"activeCount":56},[],{"trials":2656,"activeCount":56},[],{"intervention":2658,"totalTrials":52,"cells":2659},"Estradiol\u002FMedroxyprogesterone acetate",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2661,"activeCount":56},[],{"trials":2663,"activeCount":56},[],{"trials":2665,"activeCount":56},[2666],{"nctId":2667,"briefTitle":2668,"status":364,"phases":2669,"primaryCompletion":2670,"completion":2670,"start":2671,"enrollment":56,"conditions":2672,"interventions":2673},"NCT00370019","Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure",[46],"2011-12-12","2006-08-25",[1554],[2658],{"trials":2675,"activeCount":56},[],{"trials":2677,"activeCount":56},[],{"trials":2679,"activeCount":56},[],{"intervention":2681,"totalTrials":52,"cells":2682},"bromocriptine",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2684,"activeCount":56},[],{"trials":2686,"activeCount":56},[],{"trials":2688,"activeCount":56},[2689],{"nctId":2690,"briefTitle":2691,"status":2692,"phases":2693,"enrollment":1792,"conditions":2694,"interventions":2695},"NCT00004300","Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis","SUSPENDED",[46],[152,151],[2681,2696],"sertraline hydrochloride",{"trials":2698,"activeCount":56},[],{"trials":2700,"activeCount":56},[],{"trials":2702,"activeCount":56},[],{"intervention":2696,"totalTrials":52,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2715,"PHASE4":2717,"NA":2719},{"trials":2706,"activeCount":56},[],{"trials":2708,"activeCount":56},[],{"trials":2710,"activeCount":56},[2711],{"nctId":2690,"briefTitle":2691,"status":2692,"phases":2712,"enrollment":1792,"conditions":2713,"interventions":2714},[46],[152,151],[2681,2696],{"trials":2716,"activeCount":56},[],{"trials":2718,"activeCount":56},[],{"trials":2720,"activeCount":56},[],{"intervention":2722,"totalTrials":52,"cells":2723},"Liraglutide",{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2725,"activeCount":56},[],{"trials":2727,"activeCount":56},[],{"trials":2729,"activeCount":56},[2730],{"nctId":2731,"briefTitle":2732,"status":123,"phases":2733,"primaryCompletion":2734,"completion":2735,"start":2736,"enrollment":1302,"conditions":2737,"interventions":2739},"NCT04883346","Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy",[46],"2024-03-15","2024-04-30","2021-06-21",[18,2738],"Status Post Sleeve Gastrectomy",[2722],{"trials":2741,"activeCount":56},[],{"trials":2743,"activeCount":56},[],{"trials":2745,"activeCount":56},[],{"intervention":2747,"totalTrials":52,"cells":2748},"recombinant adenovirus containing the ornithine transcarbamylase gene",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2761,"PHASE3":2763,"PHASE4":2765,"NA":2767},{"trials":2750,"activeCount":56},[],{"trials":2752,"activeCount":56},[2753],{"nctId":2754,"briefTitle":2755,"status":587,"phases":2756,"start":2757,"conditions":2758,"interventions":2760},"NCT00004386","Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency",[45],"1995-10",[2759],"Ornithine Transcarbamylase Deficiency Disease",[2747],{"trials":2762,"activeCount":56},[],{"trials":2764,"activeCount":56},[],{"trials":2766,"activeCount":56},[],{"trials":2768,"activeCount":56},[],{"intervention":1509,"totalTrials":52,"cells":2770},{"EARLY_PHASE1":2771,"PHASE1":2773,"PHASE2":2779,"PHASE3":2781,"PHASE4":2783,"NA":2785},{"trials":2772,"activeCount":56},[],{"trials":2774,"activeCount":56},[2775],{"nctId":1502,"briefTitle":1503,"status":123,"phases":2776,"completion":829,"start":1505,"enrollment":1506,"conditions":2777,"interventions":2778},[45],[21],[1486,1509],{"trials":2780,"activeCount":56},[],{"trials":2782,"activeCount":56},[],{"trials":2784,"activeCount":56},[],{"trials":2786,"activeCount":56},[],{"intervention":2788,"totalTrials":52,"cells":2789},"Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine",{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2791,"activeCount":56},[],{"trials":2793,"activeCount":56},[2794],{"nctId":2795,"briefTitle":2796,"status":364,"phases":2797,"primaryCompletion":2798,"completion":2798,"start":2799,"enrollment":56,"conditions":2800,"interventions":2804},"NCT00977899","Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine",[45],"2013-03-05","2009-08-20",[2801,2802,2803],"Malaria","Malaria Vaccines","Plasmodium Falciparum Malaria",[2788],{"trials":2806,"activeCount":56},[],{"trials":2808,"activeCount":56},[],{"trials":2810,"activeCount":56},[],{"trials":2812,"activeCount":56},[],{"intervention":2814,"totalTrials":52,"cells":2815},"Dexmedetomine",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2829,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2817,"activeCount":56},[],{"trials":2819,"activeCount":56},[2820],{"nctId":2821,"briefTitle":2822,"status":123,"phases":2823,"completion":2824,"start":391,"enrollment":2825,"conditions":2826,"interventions":2828},"NCT00459082","A Pharmacokinetic Study of Dexmedetomine in Infants",[45],"2006-11",36,[2827],"Cardiac Surgical Procedures",[2814],{"trials":2830,"activeCount":56},[],{"trials":2832,"activeCount":56},[],{"trials":2834,"activeCount":56},[],{"trials":2836,"activeCount":56},[],{"intervention":2838,"totalTrials":52,"cells":2839},"Azithromycin",{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2854,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2841,"activeCount":56},[],{"trials":2843,"activeCount":56},[2844],{"nctId":2845,"briefTitle":2846,"status":123,"phases":2847,"start":2848,"enrollment":2849,"conditions":2850,"interventions":2853},"NCT00760279","An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates",[45],"2005-09",16,[2851,2852],"Ureaplasma","Bacterial Infection",[2838],{"trials":2855,"activeCount":56},[],{"trials":2857,"activeCount":56},[],{"trials":2859,"activeCount":56},[],{"trials":2861,"activeCount":56},[],{"intervention":2863,"totalTrials":52,"cells":2864},"Shigella Sonnei O-SPC\u002FrBRU",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2878,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2866,"activeCount":56},[],{"trials":2868,"activeCount":56},[2869],{"nctId":2870,"briefTitle":2871,"status":123,"phases":2872,"primaryCompletion":2873,"completion":2873,"start":2874,"enrollment":2138,"conditions":2875,"interventions":2877},"NCT01369927","Shigella Sonnel O-SPC\u002FrBRU Conjugate Vaccine",[45],"2013-04-24","2011-05-15",[2876,782],"Immunogenicity",[2863],{"trials":2879,"activeCount":56},[],{"trials":2881,"activeCount":56},[],{"trials":2883,"activeCount":56},[],{"trials":2885,"activeCount":56},[],{"intervention":2887,"totalTrials":52,"cells":2888},"lorazepam",{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2901,"PHASE3":2903,"PHASE4":2905,"NA":2907},{"trials":2890,"activeCount":56},[],{"trials":2892,"activeCount":56},[2893],{"nctId":2894,"briefTitle":2895,"status":123,"phases":2896,"primaryCompletion":2897,"completion":778,"start":829,"enrollment":2898,"conditions":2899,"interventions":2900},"NCT00114569","Lorazepam for the Treatment of Status Epilepticus in Children",[45],"2007-04",69,[1122],[2887],{"trials":2902,"activeCount":56},[],{"trials":2904,"activeCount":56},[],{"trials":2906,"activeCount":56},[],{"trials":2908,"activeCount":56},[],{"intervention":2910,"totalTrials":52,"cells":2911},"Codeine",{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2927,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2913,"activeCount":56},[],{"trials":2915,"activeCount":56},[2916],{"nctId":2917,"briefTitle":2918,"status":123,"phases":2919,"primaryCompletion":2920,"completion":2920,"start":2921,"enrollment":2922,"conditions":2923,"interventions":2926},"NCT01322204","Codeine in Mechanically Ventilated Neonates",[45],"2013-03-06","2008-08",6,[2924,2925],"Mechanically Ventilated Neonates","Painful Procedures in Newborns",[2910],{"trials":2928,"activeCount":56},[],{"trials":2930,"activeCount":56},[],{"trials":2932,"activeCount":56},[],{"trials":2934,"activeCount":56},[],{"intervention":2936,"totalTrials":52,"cells":2937},"epoetin",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2949,"PHASE3":2951,"PHASE4":2953,"NA":2955},{"trials":2939,"activeCount":56},[],{"trials":2941,"activeCount":56},[2942],{"nctId":2943,"briefTitle":2944,"status":109,"phases":2945,"enrollment":1506,"conditions":2946,"interventions":2948},"NCT00491413","Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth",[45],[2947],"Asphyxia",[2936],{"trials":2950,"activeCount":56},[],{"trials":2952,"activeCount":56},[],{"trials":2954,"activeCount":56},[],{"trials":2956,"activeCount":56},[],{"intervention":2958,"totalTrials":52,"cells":2959},"Anthrax Vaccine",{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2974,"PHASE3":2976,"PHASE4":2978,"NA":2980},{"trials":2961,"activeCount":56},[],{"trials":2963,"activeCount":56},[2964],{"nctId":2965,"briefTitle":2966,"status":123,"phases":2967,"completion":2968,"start":2969,"enrollment":2970,"conditions":2971,"interventions":2973},"NCT00114621","Anthrax Vaccine Clinical Trials",[45],"2011-05-25","2004-09-08",93,[2972],"Anthrax",[2958],{"trials":2975,"activeCount":56},[],{"trials":2977,"activeCount":56},[],{"trials":2979,"activeCount":56},[],{"trials":2981,"activeCount":56},[],{"intervention":2983,"totalTrials":52,"cells":2984},"BB IND 6989",{"EARLY_PHASE1":2985,"PHASE1":2987,"PHASE2":2997,"PHASE3":2999,"PHASE4":3001,"NA":3003},{"trials":2986,"activeCount":56},[],{"trials":2988,"activeCount":56},[2989],{"nctId":2990,"briefTitle":2991,"status":123,"phases":2992,"completion":2993,"start":2994,"enrollment":591,"conditions":2995,"interventions":2996},"NCT00277147","Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine",[45],"2008-09-17","2006-01-09",[1733],[2983],{"trials":2998,"activeCount":56},[],{"trials":3000,"activeCount":56},[],{"trials":3002,"activeCount":56},[],{"trials":3004,"activeCount":56},[],{"intervention":3006,"totalTrials":52,"cells":3007},"CP",{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3020,"PHASE3":3022,"PHASE4":3024,"NA":3026},{"trials":3009,"activeCount":56},[],{"trials":3011,"activeCount":56},[3012],{"nctId":3013,"briefTitle":3014,"status":364,"phases":3015,"primaryCompletion":3016,"completion":3016,"start":3017,"enrollment":56,"conditions":3018,"interventions":3019},"NCT01399424","Shigella Sonnei OSPC-rDT Conjugate Vaccine",[45],"2012-04-25","2011-07-16",[782],[3006],{"trials":3021,"activeCount":56},[],{"trials":3023,"activeCount":56},[],{"trials":3025,"activeCount":56},[],{"trials":3027,"activeCount":56},[],{"intervention":3029,"totalTrials":52,"cells":3030},"Betahistine Hydrochloride",{"EARLY_PHASE1":3031,"PHASE1":3033,"PHASE2":3046,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3032,"activeCount":56},[],{"trials":3034,"activeCount":56},[3035],{"nctId":3036,"briefTitle":3037,"status":123,"phases":3038,"primaryCompletion":3039,"completion":3039,"start":3040,"enrollment":3041,"conditions":3042,"interventions":3045},"NCT00459992","Effects of Betahistine Hydrochloride in Overweight Women",[45],"2011-02-14","2007-04-10",150,[18,3043,3044],"Overweight","Overnutrition",[3029],{"trials":3047,"activeCount":56},[],{"trials":3049,"activeCount":56},[],{"trials":3051,"activeCount":56},[],{"trials":3053,"activeCount":56},[],{"intervention":3055,"totalTrials":52,"cells":3056},"Micafungin lock therapy",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3058,"activeCount":56},[],{"trials":3060,"activeCount":56},[3061],{"nctId":3062,"briefTitle":3063,"status":587,"phases":3064,"primaryCompletion":913,"completion":2060,"start":250,"enrollment":1633,"conditions":3065,"interventions":3067},"NCT00809887","Micafungin Lock Therapy",[45],[3066],"Catheter-Related Fungal Infections",[3055],{"trials":3069,"activeCount":56},[],{"trials":3071,"activeCount":56},[],{"trials":3073,"activeCount":56},[],{"trials":3075,"activeCount":56},[],{"intervention":808,"totalTrials":419,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3100,"NA":3102},{"trials":3079,"activeCount":56},[],{"trials":3081,"activeCount":56},[],{"trials":3083,"activeCount":56},[],{"trials":3085,"activeCount":56},[3086,3090],{"nctId":800,"briefTitle":801,"status":364,"phases":3087,"completion":803,"start":804,"enrollment":56,"conditions":3088,"interventions":3089},[47],[806],[808,789],{"nctId":3091,"briefTitle":3092,"status":109,"phases":3093,"primaryCompletion":3094,"completion":315,"start":3095,"enrollment":3096,"conditions":3097,"interventions":3099},"NCT00868010","Enhancing Rehabilitation After Stroke",[47],"2013-08","2009-03",200,[3098],"Ischemic Stroke",[808],{"trials":3101,"activeCount":56},[],{"trials":3103,"activeCount":56},[3104],{"nctId":3105,"briefTitle":3106,"status":123,"phases":3107,"start":3108,"enrollment":3109,"conditions":3110,"interventions":3111},"NCT00004807","Study of the Pathogenesis of Rett Syndrome",[49],"1995-01",120,[917],[919,3112,3113],"topiramate","Donepezil",{"intervention":3115,"totalTrials":11,"cells":3116},"Topiramate",{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3118,"activeCount":56},[],{"trials":3120,"activeCount":56},[],{"trials":3122,"activeCount":56},[],{"trials":3124,"activeCount":56},[],{"trials":3126,"activeCount":56},[],{"trials":3128,"activeCount":56},[3129,3138],{"nctId":3130,"briefTitle":3131,"status":123,"phases":3132,"primaryCompletion":3133,"start":3134,"enrollment":28,"conditions":3135,"interventions":3137},"NCT00065923","Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome",[49],"2005-12","2002-07",[3136,153],"Prader-Willi Syndrome",[3115],{"nctId":3105,"briefTitle":3106,"status":123,"phases":3139,"start":3108,"enrollment":3109,"conditions":3140,"interventions":3141},[49],[917],[919,3112,3113],{"intervention":1709,"totalTrials":11,"cells":3143},{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3154,"PHASE4":3156,"NA":3158},{"trials":3145,"activeCount":56},[],{"trials":3147,"activeCount":56},[],{"trials":3149,"activeCount":56},[3150],{"nctId":1699,"briefTitle":1700,"status":587,"phases":3151,"primaryCompletion":1702,"completion":1702,"start":1703,"enrollment":1704,"conditions":3152,"interventions":3153},[46],[1706,1707],[1709,1690],{"trials":3155,"activeCount":56},[],{"trials":3157,"activeCount":56},[],{"trials":3159,"activeCount":56},[3160],{"nctId":3161,"briefTitle":3162,"status":123,"phases":3163,"primaryCompletion":3164,"completion":3164,"start":3165,"enrollment":3166,"conditions":3167,"interventions":3169},"NCT00392457","Investigating the Regulation of Reproductive Hormones in Adult Men",[49],"2007-02","1995-07",175,[1707,1706,3168],"Gonadal Disorder",[3170,1709],"ketoconazole",{"intervention":919,"totalTrials":11,"cells":3172},{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3179,"PHASE4":3185,"NA":3187},{"trials":3174,"activeCount":56},[],{"trials":3176,"activeCount":56},[],{"trials":3178,"activeCount":56},[],{"trials":3180,"activeCount":56},[3181],{"nctId":910,"briefTitle":911,"status":109,"phases":3182,"completion":913,"start":914,"enrollment":915,"conditions":3183,"interventions":3184},[47],[917],[919,899],{"trials":3186,"activeCount":56},[],{"trials":3188,"activeCount":56},[3189],{"nctId":3105,"briefTitle":3106,"status":123,"phases":3190,"start":3108,"enrollment":3109,"conditions":3191,"interventions":3192},[49],[917],[919,3112,3113],{"intervention":2488,"totalTrials":11,"cells":3194},{"EARLY_PHASE1":3195,"PHASE1":3197,"PHASE2":3199,"PHASE3":3205,"PHASE4":3207,"NA":3209},{"trials":3196,"activeCount":56},[],{"trials":3198,"activeCount":56},[],{"trials":3200,"activeCount":56},[3201],{"nctId":2480,"briefTitle":2481,"status":364,"phases":3202,"completion":2483,"start":589,"enrollment":2484,"conditions":3203,"interventions":3204},[46],[2486],[2488,2471,2489],{"trials":3206,"activeCount":56},[],{"trials":3208,"activeCount":56},[],{"trials":3210,"activeCount":56},[3211],{"nctId":3212,"briefTitle":3213,"status":123,"phases":3214,"primaryCompletion":125,"completion":125,"start":2461,"enrollment":3215,"conditions":3216,"interventions":3221},"NCT00494208","TDSM- Testosterone Dose Response in Surgically Menopausal Women",[49],270,[3217,3218,3219,3220],"Hysterectomy","Ovariectomy","Menopause","Testosterone Deficiency",[2488],{"intervention":3223,"totalTrials":52,"cells":3224},"Vitamin A supplementation",{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3229,"PHASE3":3231,"PHASE4":3233,"NA":3235},{"trials":3226,"activeCount":56},[],{"trials":3228,"activeCount":56},[],{"trials":3230,"activeCount":56},[],{"trials":3232,"activeCount":56},[],{"trials":3234,"activeCount":56},[],{"trials":3236,"activeCount":56},[3237],{"nctId":3238,"briefTitle":3239,"status":109,"phases":3240,"completion":391,"start":3241,"enrollment":3242,"conditions":3243,"interventions":3245},"NCT00063596","Vitamin A Supplementation in Preterm Infants",[49],"2000-01",220,[3244],"Infant, Premature",[3223],{"intervention":3247,"totalTrials":52,"cells":3248},"oCRH",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3257,"NA":3259},{"trials":3250,"activeCount":56},[],{"trials":3252,"activeCount":56},[],{"trials":3254,"activeCount":56},[],{"trials":3256,"activeCount":56},[],{"trials":3258,"activeCount":56},[],{"trials":3260,"activeCount":56},[3261],{"nctId":3262,"briefTitle":3263,"status":123,"phases":3264,"start":3265,"enrollment":3266,"conditions":3267,"interventions":3273},"NCT00001452","Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex",[],"1995-12-14",1387,[3268,3269,3270,3271,3272],"Cushing's Syndrome","Pituitary Adenoma","Carney Complex","Primary Pigmented Nodular Adrenocortical Disease","Peutz-Jeghers Syndrome",[3247],{"intervention":3275,"totalTrials":52,"cells":3276},"succimer",{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3281,"PHASE3":3283,"PHASE4":3285,"NA":3287},{"trials":3278,"activeCount":56},[],{"trials":3280,"activeCount":56},[],{"trials":3282,"activeCount":56},[],{"trials":3284,"activeCount":56},[],{"trials":3286,"activeCount":56},[],{"trials":3288,"activeCount":56},[3289],{"nctId":3290,"briefTitle":3291,"status":123,"phases":3292,"completion":1324,"start":3293,"enrollment":3166,"conditions":3294,"interventions":3296},"NCT00004838","Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children",[49],"1997-09",[3295],"Lead Poisoning",[3275],{"intervention":3298,"totalTrials":52,"cells":3299},"Ovine Corticotropin-Releasing Hormone",{"EARLY_PHASE1":3300,"PHASE1":3302,"PHASE2":3304,"PHASE3":3306,"PHASE4":3308,"NA":3310},{"trials":3301,"activeCount":56},[],{"trials":3303,"activeCount":56},[],{"trials":3305,"activeCount":56},[],{"trials":3307,"activeCount":56},[],{"trials":3309,"activeCount":56},[],{"trials":3311,"activeCount":56},[3312],{"nctId":3313,"briefTitle":3314,"status":123,"phases":3315,"completion":111,"start":3316,"enrollment":3317,"conditions":3318,"interventions":3321},"NCT00001180","Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency",[],"1982-03",2250,[3319,3320,3268,21],"Adrenal Gland Hyperfunction","Adrenal Gland Hypofunction",[3298],{"intervention":3323,"totalTrials":52,"cells":3324},"Ethinyl estradiol\u002Flevonorgestrel",{"EARLY_PHASE1":3325,"PHASE1":3327,"PHASE2":3329,"PHASE3":3331,"PHASE4":3333,"NA":3335},{"trials":3326,"activeCount":56},[],{"trials":3328,"activeCount":56},[],{"trials":3330,"activeCount":56},[],{"trials":3332,"activeCount":56},[],{"trials":3334,"activeCount":56},[],{"trials":3336,"activeCount":56},[3337],{"nctId":3338,"briefTitle":3339,"status":123,"phases":3340,"completion":1542,"start":1552,"enrollment":3341,"conditions":3342,"interventions":3343},"NCT00006324","Hormonal Birth Control and the Risk of Acquiring HIV",[49],6360,[30],[3323,3344],"Medroxyprogesterone acetate",{"intervention":3344,"totalTrials":52,"cells":3346},{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3353,"PHASE4":3355,"NA":3357},{"trials":3348,"activeCount":56},[],{"trials":3350,"activeCount":56},[],{"trials":3352,"activeCount":56},[],{"trials":3354,"activeCount":56},[],{"trials":3356,"activeCount":56},[],{"trials":3358,"activeCount":56},[3359],{"nctId":3338,"briefTitle":3339,"status":123,"phases":3360,"completion":1542,"start":1552,"enrollment":3341,"conditions":3361,"interventions":3362},[49],[30],[3323,3344],{"intervention":3364,"totalTrials":52,"cells":3365},"Methadone",{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3370,"PHASE3":3372,"PHASE4":3374,"NA":3376},{"trials":3367,"activeCount":56},[],{"trials":3369,"activeCount":56},[],{"trials":3371,"activeCount":56},[],{"trials":3373,"activeCount":56},[],{"trials":3375,"activeCount":56},[],{"trials":3377,"activeCount":56},[3378],{"nctId":3379,"briefTitle":3380,"status":123,"phases":3381,"primaryCompletion":188,"start":189,"enrollment":3382,"conditions":3383,"interventions":3384},"NCT00006448","Treatment of Chronic Pain After Spinal Cord Injury (SCI) or Amputation",[49],400,[203,192,193],[3364],{"intervention":3170,"totalTrials":52,"cells":3386},{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3393,"PHASE4":3395,"NA":3397},{"trials":3388,"activeCount":56},[],{"trials":3390,"activeCount":56},[],{"trials":3392,"activeCount":56},[],{"trials":3394,"activeCount":56},[],{"trials":3396,"activeCount":56},[],{"trials":3398,"activeCount":56},[3399],{"nctId":3161,"briefTitle":3162,"status":123,"phases":3400,"primaryCompletion":3164,"completion":3164,"start":3165,"enrollment":3166,"conditions":3401,"interventions":3402},[49],[1707,1706,3168],[3170,1709],{"intervention":3404,"totalTrials":52,"cells":3405},"thyrotropin-releasing hormone",{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3407,"activeCount":56},[],{"trials":3409,"activeCount":56},[],{"trials":3411,"activeCount":56},[],{"trials":3413,"activeCount":56},[],{"trials":3415,"activeCount":56},[],{"trials":3417,"activeCount":56},[3418],{"nctId":3419,"briefTitle":3420,"status":123,"phases":3421,"completion":3422,"start":3423,"enrollment":3424,"conditions":3425,"interventions":3427},"NCT00004840","Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants",[49],"1998-06","1998-05",996,[3426],"Respiratory Distress Syndrome",[3404],{"intervention":3429,"totalTrials":52,"cells":3430},"Cholesterol Suspension",{"EARLY_PHASE1":3431,"PHASE1":3433,"PHASE2":3435,"PHASE3":3437,"PHASE4":3439,"NA":3441},{"trials":3432,"activeCount":56},[],{"trials":3434,"activeCount":56},[],{"trials":3436,"activeCount":56},[],{"trials":3438,"activeCount":56},[],{"trials":3440,"activeCount":56},[],{"trials":3442,"activeCount":56},[3443],{"nctId":3444,"briefTitle":3445,"status":123,"phases":3446,"start":3447,"enrollment":3448,"conditions":3449,"interventions":3451},"NCT00001721","Study of Smith-Lemli-Opitz Syndrome",[],"1998-09-13",130,[3450],"Smith-Lemli-Opitz Syndrome",[3429,3452,3453],"CRH","Cholesterol",{"intervention":3452,"totalTrials":52,"cells":3455},{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3457,"activeCount":56},[],{"trials":3459,"activeCount":56},[],{"trials":3461,"activeCount":56},[],{"trials":3463,"activeCount":56},[],{"trials":3465,"activeCount":56},[],{"trials":3467,"activeCount":56},[3468],{"nctId":3444,"briefTitle":3445,"status":123,"phases":3469,"start":3447,"enrollment":3448,"conditions":3470,"interventions":3471},[],[3450],[3429,3452,3453],{"intervention":3453,"totalTrials":52,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3475,"activeCount":56},[],{"trials":3477,"activeCount":56},[],{"trials":3479,"activeCount":56},[],{"trials":3481,"activeCount":56},[],{"trials":3483,"activeCount":56},[],{"trials":3485,"activeCount":56},[3486],{"nctId":3444,"briefTitle":3445,"status":123,"phases":3487,"start":3447,"enrollment":3448,"conditions":3488,"interventions":3489},[],[3450],[3429,3452,3453],{"intervention":3491,"totalTrials":52,"cells":3492},"Drug: FSH",{"EARLY_PHASE1":3493,"PHASE1":3495,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3494,"activeCount":56},[],{"trials":3496,"activeCount":56},[],{"trials":3498,"activeCount":56},[],{"trials":3500,"activeCount":56},[],{"trials":3502,"activeCount":56},[],{"trials":3504,"activeCount":56},[3505],{"nctId":3506,"briefTitle":3507,"status":123,"phases":3508,"primaryCompletion":3509,"completion":3509,"start":3510,"enrollment":3511,"conditions":3512,"interventions":3513},"NCT00006156","Feasibility Study for Development of an Early Test for Ovarian Failure",[49],"2012-01","2000-08",49,[21,1554],[3491],{"intervention":3515,"totalTrials":52,"cells":3516},"acetylsalicylic-acid",{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3521,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3518,"activeCount":56},[],{"trials":3520,"activeCount":56},[],{"trials":3522,"activeCount":56},[],{"trials":3524,"activeCount":56},[],{"trials":3526,"activeCount":56},[],{"trials":3528,"activeCount":56},[3529],{"nctId":3530,"briefTitle":3531,"status":123,"phases":3532,"primaryCompletion":2135,"completion":2135,"start":3533,"enrollment":3534,"conditions":3535,"interventions":3538},"NCT00467363","The Effects of Aspirin in Gestation and Reproduction",[49],"2007-06",1228,[3536,3537],"Birth","Spontaneous Abortion",[3515],{"intervention":3540,"totalTrials":52,"cells":3541},"Depo Medroxyprogesterone acetate",{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3548,"PHASE4":3550,"NA":3552},{"trials":3543,"activeCount":56},[],{"trials":3545,"activeCount":56},[],{"trials":3547,"activeCount":56},[],{"trials":3549,"activeCount":56},[],{"trials":3551,"activeCount":56},[],{"trials":3553,"activeCount":56},[3554],{"nctId":3555,"briefTitle":3556,"status":587,"phases":3557,"completion":3558,"start":3293,"enrollment":3559,"conditions":3560,"interventions":3563},"NCT00091728","Hormonal Contraception and Risk of Chlamydia and Gonorrhea",[],"2001-08",1200,[3561,3562],"Chlamydia Infection","Neisseriaceae Infection",[3540,3564],"Combined oral contraceptives",{"intervention":3564,"totalTrials":52,"cells":3566},{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3568,"activeCount":56},[],{"trials":3570,"activeCount":56},[],{"trials":3572,"activeCount":56},[],{"trials":3574,"activeCount":56},[],{"trials":3576,"activeCount":56},[],{"trials":3578,"activeCount":56},[3579],{"nctId":3555,"briefTitle":3556,"status":587,"phases":3580,"completion":3558,"start":3293,"enrollment":3559,"conditions":3581,"interventions":3582},[],[3561,3562],[3540,3564]]